Tang Zhiqiang, Xu Shuyun, Zhao Shucheng, Luo Zhihui, Tang Yuanli, Zhang Yuanjun
Department of Emergency Medical, The First People's Hospital of Ziyang, Ziyang 641300, China.
Department of Emergency Medical, ShangJin Hospital of West China Hospital, Sichuan University, Chengdu 611730, China.
Clin Neurol Neurosurg. 2025 Feb;249:108648. doi: 10.1016/j.clineuro.2024.108648. Epub 2024 Nov 19.
This study aims to explore the clinical significance of long non-coding RNA, myocardial infarction-associated transcript (MIAT), in patients with traumatic brain injury (TBI).
Retrospective inclusion of TBI patients meeting clinical criteria with complete data, alongside healthy controls. RT-qPCR was used to detect the expression of the serum MIAT. Based on the Glasgow Coma Scale (GCS) scores, patients were categorized into mild, moderate, and severe TBI groups. The potential risk factors for severity were examined using logistic regression analysis. The one-year prognosis for TBI was determined using the Glasgow Outcome Scale (GOS) score. The correlation of MIAT levels with GCS scores and GOS scores was determined using Pearson correlation analysis. The effect of MIAT on the severity and poor prognosis was assessed using the receiver operating characteristic curve. Lastly, the dual-luciferase reporter assay confirmed the relationship between the MIAT and miR-221-3p.
110 patients with TBI and 106 healthy controls were included. Serum MIAT levels were strikingly higher in patients with TBI compared to controls, whereas miR-221-3p levels were lower. As the severity of TBI increases, the expression of MIAT gradually elevated. A notable negative correlation was observed between serum MIAT levels and both the GCS and GOS scores. MIAT levels were effective in distinguishing patients with moderate TBI from those with mild or severe TBI, with a sensitivity of 82.35 % and 88.64 % and a specificity of 86.67 % and 86.27 %. Furthermore, elevated MIAT levels, with a sensitivity of 85.00 % and a specificity of 75.56 %, can predict the clinical outcomes of patients with TBI. miR-221-3p levels were negatively correlated with MIAT expression in patients with TBI, and MIAT directly targeted miR-221-3p.
Serum MIAT could serve as a diagnostic marker of severity and may predict poor prognosis in patients with TBI. This study proposes fresh perspectives on the pursuit of biomarkers and the management of patients with TBI.
本研究旨在探讨长链非编码RNA心肌梗死相关转录本（MIAT）在创伤性脑损伤（TBI）患者中的临床意义。
回顾性纳入符合临床标准且数据完整的TBI患者以及健康对照者。采用逆转录定量聚合酶链反应（RT-qPCR）检测血清MIAT的表达。根据格拉斯哥昏迷量表（GCS）评分，将患者分为轻度、中度和重度TBI组。使用逻辑回归分析检查严重程度的潜在危险因素。采用格拉斯哥预后量表（GOS）评分确定TBI患者的一年预后。使用Pearson相关分析确定MIAT水平与GCS评分和GOS评分的相关性。采用受试者工作特征曲线评估MIAT对严重程度和不良预后的影响。最后，双荧光素酶报告基因检测证实了MIAT与miR-221-3p之间的关系。
纳入110例TBI患者和106例健康对照者。与对照组相比，TBI患者血清MIAT水平显著更高，而miR-221-3p水平更低。随着TBI严重程度的增加，MIAT的表达逐渐升高。血清MIAT水平与GCS和GOS评分之间均观察到显著的负相关。MIAT水平在区分中度TBI患者与轻度或重度TBI患者方面有效，敏感性分别为82.35%和88.64%，特异性分别为86.67%和86.27%。此外，MIAT水平升高，敏感性为85.00%，特异性为75.56%，可预测TBI患者的临床结局。TBI患者中miR-221-3p水平与MIAT表达呈负相关，且MIAT直接靶向miR-221-3p。
血清MIAT可作为严重程度的诊断标志物，并可能预测TBI患者的不良预后。本研究为寻找生物标志物和TBI患者的管理提供了新的视角。
